Parkinson's Disease, Primates, and Gene Therapy: Vive La Différence?

Overview

Journal Mov Disord

Date 2011 Feb 16

PMID 21322013

Citations 2

Authors

Travis B Lewis

David G Standaert

Affiliations

Soon will be listed here.

Citing Articles

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?.

Volpicelli-Daley L, Kirik D, Stoyka L, Standaert D, Harms A J Neurochem. 2016; 139 Suppl 1:131-155.

PMID: 27018978 PMC: 5040622. DOI: 10.1111/jnc.13627.

Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes.

Volpicelli-Daley L, Gamble K, Schultheiss C, Riddle D, West A, Lee V Mol Biol Cell. 2014; 25(25):4010-23.

PMID: 25298402 PMC: 4263445. DOI: 10.1091/mbc.E14-02-0741.

References

Slevin J, Gash D, Smith C, Gerhardt G, Kryscio R, Chebrolu H . Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg. 2007; 106(4):614-20. DOI: 10.3171/jns.2007.106.4.614. View

Nutt J, Burchiel K, Comella C, Jankovic J, Lang A, Laws Jr E . Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003; 60(1):69-73. DOI: 10.1212/wnl.60.1.69. View

Lehtonen E, Bonnaud F, Melas C, Lubansu A, Malgrange B, Chtarto A . AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon. Neuroreport. 2002; 13(12):1503-7. DOI: 10.1097/00001756-200208270-00003. View

Kordower J, Herzog C, Dass B, Bakay R, Stansell 3rd J, Gasmi M . Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006; 60(6):706-15. DOI: 10.1002/ana.21032. View

Manfredsson F, Tumer N, Erdos B, Landa T, Broxson C, Sullivan L . Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther. 2009; 17(6):980-91. PMC: 2835185. DOI: 10.1038/mt.2009.45. View

Morfini G, Burns M, Binder L, Kanaan N, LaPointe N, Bosco D . Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009; 29(41):12776-86. PMC: 2801051. DOI: 10.1523/JNEUROSCI.3463-09.2009. View

St Martin J, Klucken J, Outeiro T, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I . Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007; 100(6):1449-57. DOI: 10.1111/j.1471-4159.2006.04310.x. View

Standaert D, Yacoubian T . Target validation: the Parkinson disease perspective. Dis Model Mech. 2010; 3(5-6):259-62. DOI: 10.1242/dmm.004192. View

Herzog C, Brown L, Gammon D, Kruegel B, Lin R, Wilson A . Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009; 64(4):602-12. DOI: 10.1227/01.NEU.0000340682.06068.01. View

10.

Marks Jr W, Bartus R, Siffert J, Davis C, Lozano A, Boulis N . Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010; 9(12):1164-1172. DOI: 10.1016/S1474-4422(10)70254-4. View

11.

Su X, Kells A, Huang E, Lee H, Hadaczek P, Beyer J . Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther. 2009; 20(12):1627-40. PMC: 2861959. DOI: 10.1089/hum.2009.103. View

12.

Marks Jr W, Ostrem J, Verhagen L, Starr P, Larson P, Bakay R . Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008; 7(5):400-8. DOI: 10.1016/S1474-4422(08)70065-6. View

13.

Lewis T, Standaert D . Design of clinical trials of gene therapy in Parkinson disease. Exp Neurol. 2007; 209(1):41-7. DOI: 10.1016/j.expneurol.2007.08.012. View